Safety Update: ALTITUDE ‘unboost’

Safety Update: ALTITUDE ‘unboost’

by Kazeem Olalekan MRPharmS Early result from the ALiskiren Trial In Type 2 diabetes Using cardiovascular and renal Disease Endpoints (ALTITUDE) study has shown that: study patients were unlikely to benefit from aliskiren; and an increased incidence of non-fatal strokes, renal complications (including acute renal failure), hyperkalaemia

Read more

Royal Pharmaceutical Society Conference 2011–Supporting the Future of Pharmacy through education and professionalism

Royal Pharmaceutical Society Conference 2011–Supporting the Future of Pharmacy through education and professionalism

by Kazeem Olalekan MRPhamS At the recent Royal Pharmaceutical Society Conference, the strategy for supporting the future of pharmacy through education and professionalism was the theme of a break-out session. The following pieces of work are relevant: Defining professionalism (and its elements) in early career pharmacists R.

Read more

Drug Safety Update – Atypical femoral fractures with Bisphosphonates

Drug Safety Update – Atypical femoral fractures with Bisphosphonates

Atypical femoral fractures have been reported rarely with bisphosphonate therapy, mainly in patients receiving long-term treatment for osteoporosis. Discontinuation of bisphosphonate therapy in patients suspected to have an atypical femur fracture should be considered while they are evaluated, and should be based on an assessment of the

Read more

ONtrack

ONtrack

Tomorrow’s Pharmacist (1) has launched a website called ONtrack (2) to support preregistration trainees’ revision for the registration exam. There are section for open book, closed book and calculation elements of the exam. It will cost Royal Pharmaceutical Society’s associate members £25 and £35 for non-members.

Read more